3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
6
Hematologic Neoplasms
2
Waldenstrom Macroglobulinemia
1
Mature B-cell Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, B-Cell
1
Interventions
Rituximab
9
venetoclax
7
ibrutinib
7
Cyclophosphamide
7
Mycophenolic Acid
5
fludarabine phosphate
4
Whole-Body Irradiation
4
Sirolimus
4
zanubrutinib
3
pirtobrutinib
3
Peripheral Blood Stem Cell Transplantation
3
Dexamethasone
3
Cyclosporine
3
ixazomib
2
fludarabine
2
carfilzomib
2
acalabrutinib
2
Tacrolimus
2
Melphalan
2
Etoposide
2
Cyclosporins
2
Calcium Dobesilate
2
CT-P10
2
Busulfan
2
Bendamustine Hydrochloride
2
talquetamab
1
pembrolizumab
1
loncastuximab tesirine
1
brexucabtagene autoleucel
1
Vincristine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Waldenstrom Macroglobulinemia
×
ARQ531
×
90 days
×
Clear all
NCT04728893
2026-05-26
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2
Recruiting
490 enrolled